Emcure Pharmaceuticals Ltd and Sanofi India Ltd have announced a distribution and promotion partnership on Wednesday (July 16) aimed at expanding access to Sanofi’s oral anti-diabetic (OAD) products across India.Effective immediately, Emcure will take charge of distributing and promoting Sanofi’s well-established OAD brands, including Amaryl and Cetapin, while Sanofi will retain ownership and continue manufacturing the products at its facilities in India and abroad.
The collaboration is designed to leverage Emcure’s extensive distribution network and deep engagement with healthcare professionals to reach more patients living with type 2 diabetes.
Notably, there will be no employee transition from Sanofi to Emcure as part of this agreement.
Commenting on the partnership, Eric Mansion, General Manager, Pharma Southeast Asia and India at Sanofi, emphasised the urgency of addressing India’s diabetes burden.“Over 100 million Indians are living with type 2 diabetes, and more than 60% have uncontrolled blood sugar levels. With Emcure’s reach, we aim to unlock the full potential of our industry-leading OADs for patients and healthcare professionals,” Mansion said.
The collaboration is designed to leverage Emcure’s extensive distribution network and deep engagement with healthcare professionals to reach more patients living with type 2 diabetes.
Notably, there will be no employee transition from Sanofi to Emcure as part of this agreement.
Commenting on the partnership, Eric Mansion, General Manager, Pharma Southeast Asia and India at Sanofi, emphasised the urgency of addressing India’s diabetes burden.“Over 100 million Indians are living with type 2 diabetes, and more than 60% have uncontrolled blood sugar levels. With Emcure’s reach, we aim to unlock the full potential of our industry-leading OADs for patients and healthcare professionals,” Mansion said.
Satish Mehta, CEO and MD of Emcure Pharmaceuticals, stated, “This collaboration aligns with our mission to improve patient access to high-quality therapies. It complements our existing diabetes portfolio and strengthens our commitment to better diabetes care nationwide.”
Also Read: Shapoorji Pallonji’s new Pune project targets ₹800 crore revenue
Shares of Emcure Pharmaceuticals Ltd. ended at ₹1,365.00, up by 4.10%, or ₹4.10, on the BSE.
(Edited by : Ajay Vaishnav)
